Diabetic foot ulcers (DFUs) represent a major clinical challenge in the ageing population. To address this problem, rhEGF-loaded Poly-Lactic-co-Glycolic-Acid (PLGA)-Alginate microspheres (MS) were prepared by a modified w/o/w-doubleemulsion/solvent evaporation method. Different formulations were evaluated with the aim of optimising MSs properties by adding NaCl to the surfactant solution and/or the solvent removal phase and adding alginate as a second polymer. The characterization of the developed MS showed that alginate incorporation increased the encapsulation efficiency (EE) and NaCl besides increasing the EE also became the particle surface smooth and regular. Once the MS were optimised, the target loading of rhEGF was increased to 1% (PLGA-Alginate MS), and particles were sterilised by gamma radiation to provide the correct dosage for in vivo studies. In vitro cell culture assays demonstrated that neither the microencapsulation nor the sterilisation process affected rhEGF bioactivity or rhEGF wound contraction. Finally, the MS were evaluated in vivo for treatment of the full-thickness wound model in diabetised Wistar rats. rhEGF MS treated animals showed a statistically significant decrease of the wound area by days 7 and 11, a complete re-epithelisation by day 11 and an earlier resolution of the inflammatory process. Overall, these findings demonstrate the promising potential of rhEGF-loaded MS (PLGA-Alginate MS) to promote faster and more effective wound healing, and suggest its possible application in DFU treatment.
Introduction
Diabetic foot ulcers (DFUs), one of the most common complications in patients with diabetes, have become a problem in health care systems all over the world. The current increment in DFUs associated risk factors such as, ageing population, smoking and obesity can complicate and slow down the healing process (Loots, et al. 2002) . The etiology of DFU is related to the damage of blood vessels, nerves and immune system modulation, caused by the long-term hyperglycaemia suffered by diabetic patients (Cevc and Vierl 2010; Falanga 2004) . The ulcers are characterised by extracellular matrix (ECM) synthesis and a remodelling disorder due to dermal fibroblast alteration, phenotypic alteration of the matrix metalloproteinases, re-epithelisation disturbance and a persistent inflammatory response (Cook, et al. 2000) .
The administration of growth factors, involved in wound healing, has shown limited success. For example, Regranex ® (Becaplermin) is a gel containing human recombinant platelet-derived growth factor (rhPDGF) that is approved by the U.S. Food and Drug Administration (FDA). It requires daily application for neuropathic wound healing (Goldman 2004) . A postmarket epidemiologic study revised by the FDA demonstrated that, patients who had been prescribed Regranex ® three or more times had a five times increased risk of death from cancer. Nevertheless, the duration of follow-up of patients in this study was not long enough to detect new cancers. As a result, the potential risk of using Regranex ® should be weighed against the benefit for each individual patient (Update of Safety Review, June 1, 2010). There are also two commercialised treatments based on rhEGF administration. Rengen-D 150TM is a gel containing 150 µg/g of Recombinant Human Epidermal Growth Factor (rhEGF) that was commercialised in
India for the treatment of grade I or II diabetic ulcers. It requires twice daily administration, with an average treatment period of 6 weeks (Mohan 2007 (Fernandez-Montequin, et al. 2009 ). However, rhEGF´s short half life requires a continuous exposure (at least 6-12 hours) to enhance the mitogenic effect on epithelial (Hardwicke, et al. 2008; Ulubayram, et al. 2001) . Therefore, in order to achieve a significant therapeutic effect, it is necessary to optimise the administration of growth factors such as rhEGF, in terms of dose, delivery system and safety.
With the aim of overcoming the previously described limitations, we developed rhEGF polymeric microspheres using a w/o/w double-emulsion solvent evaporation method.
The microencapsulation process is used to provide a sustained and controlled release of rhEGF, avoid rhEGF inhibition by wound proteases, elude frequent drug administration and prolong treatment effectiveness (Chu, et al. 2010; Dong, et al. 2008) . rhEGF was encapsulated using PLGA (Poly D,L-Lactic-co-Glycolic Acid) and alginate. On the one hand, the PLGA polymer has the advantage of being biocompatible and biodegrades in a controlled manner (Jain 2000) .On the other hand, alginate, a natural polysaccharide, has a chemical structure similar to ECM (extracellular matrix) components. Moreover, according to Jay, et al. 2008 , the use of alginate could increase de encapsulation efficiency in cases that the amount of the encapsulating therapeutic proteins is scarce (Jay, et al. 2008) .
In this study, we optimised the preparation of rhEGF-loaded PLGA-Alginate microspheres (MS). Furthermore, in vitro experiments were undertaken to determinate the susceptibility of fibroblasts to proliferate being in contact with encapsulated rhEGF, (used as a stabiliser of the rhEGF) and 0.5 mg of polyethylene glycol 400 (PEG400).
The resulting w 1 /o emulsion was poured into a surfactant solution, containing 15 ml of 5% (w/v) polyvinyl alcohol (PVA) in miliQ water and mixed with a paddle stirrer (Biocote ® Stirrer SS20) for 60 s to perform the double emulsion (w 1 /o/w 2 ). Finally, an organic solvent removal phase comprising 400 ml of miliQ water was added and stirred for 30 min. The MS were then collected by filtration and lyophilised. This formulation was called MS1. The target loading of rhEGF in MS was 0,1% (w/w).
Different changes were included in the preparation protocol described before in order to increase the encapsulation efficiency (EE). The amount of rhEGF loaded was estimated by a commercially available Sandwich Enzyme-Linked Immunosorbent assay kit for human EGF (human EGF ELISA development kit, Peprotech). The assay was performed according to the manufacturer's instructions.
Encapsulation efficiency was calculated as the percentage of the encapsulated rhEGF, referred to the total initial amount of rhEGF used for the microsphere preparation. All the tests were performed in triplicate, and the results reported as the means ± S.D.
In vitro release studies
The rhEGF in vitro release profile was determined by incubating 5 mg of MS with 1 ml of 0.02 M phosphate-buffered saline (PBS) (pH 7.4) at 37 ± 0.5 ºC under orbital rotation at 25 rpm. The release medium was removed by centrifugation and replaced by the same quantity of PBS at predetermined intervals (Gutierro, et al. 2002) . Samples were taken at 30 min., 4, 8 and 10 h. Afterwards, once a day during the first week, and once a week up to 41 days. The amount of rhEGF in the release medium was assayed by ELISA using the protocol described in section 2.4. The rhEGF release profile was only studied in the formulations with the highest EE (MS3 and MS4) and with the highest rhEGF target loading (PLGA-Alginate MS and PLGA-Alginate MS-γ) (n=3).
2.6. In vitro cell culture studies
Cell culture
Balb/c 3T3 A31 fibroblasts (ATCC, Manassas, USA) were cultured in a complete culture medium prepared with DMEM (ATCC, Manassas, USA) and supplemented with 10% (v/v) foetal calf serum (FCS) and 1% (v/v) penicillin-streptomycin. Cells were incubated at 37ºC and 5% CO 2 and were passaged out every 2-3 days.
Bioactivity assay for rhEGF
Balb/C 3T3 cells were seeded in 96-well plates at 4500 cells/well in complete culture medium for 8 hours (n=4). Medium was replaced with 100 µl assay medium containing 0.2% calf serum and incubated overnight. Then, serial dilutions from 2000 pg/ml to 2 pg/ml of rhEGF were made in the assay medium and 100 µl of each dilution was added.
The following groups were assayed (n=4) 
In vitro migration assay
Collagen type I coated 6-well plates were seeded with 10 6 Balb/C 3T3 cells/ml in complete medium and cultured at 37ºC for 24 h to form a confluent monolayer. Gaps, of approximately 0.9 mm in width, were created by scratching the plates with a sterile pipette tip (Walter, et al. 2010) . The medium was immediately removed and replaced with (i) 15 ng/ml of free rhEGF in serum-free DMEM, (ii) 15 ng/mL rhEGF obtained from 15 day long in vitro release studies (PLGA-Alginate MS) in serum-free supplemented DMEM and (iii) fresh serum-free medium. The width average of the gaps was calculated from the images taken by a microscope at three different sites from each well using ImageJ ® software. Photographs were taken at 0, 5, 18 and 24 h after wound creation. Moreover, cell cultures were recorded during 24 h by microscope (Biostation IM-Q, Nikon) in order to observe cell migration and proliferation. blood glucose levels exceeded 300 mg/dl (Li, et al. 2008 ).
Wound induction and experimental animal groups
2 wounds of 1 cm in diameter at each side of the midline, were created on the raced dorsum of 1 week diabetised rats (anesthetised by isoflurane inhalation). Full-thickness wounds extending through the panniculus carnosus were excised using a sterile surgical blade G21. A donut-shaped silicone splint 1.5 cm in diameter was sutured around the wound with a 4-0 nylon suture (Aragó, Barcelona) preventing wound contraction, the major healing process in rodents, and allowing healing by re-epithelisation and granulation tissue formation (the manner in which human skin heals) (Michaels, et al. 2007 ). Animals were divided into the following 5 groups (n=12): (i) untreated control,
(ii) vehicle control (0.9% saline and 0.5% carboxymethylcellulose buffer), (iii) empty MS control, (iv) 75 µg of free rhEGF and (v) 75 µg of rhEGF MS (PLGA-Alginate MS)
group. MS previously resuspended in 0.5 ml vehicle and vehicle treatments (0.5 ml)
were administered by a unique intralesional injection with a 23 G needle and deepening it downward into the wound bottom in circles and centripetally ensuring a uniform distribution. Free rhEGF resuspended in 0.5 ml vehicle was injected in the wound twice a week. After the treatment administration, wounds were covered with one layer of petrolatum gauze (Tegraderm ® 3M) and two layers of sterilised adhesive. A brief description of the study protocol is shown in Table 2 .
Serial wound analysis
Blood glucose levels were measured 7 and 3 days before wounding and at days 0, 5, 9, 14 and 17 post-wounding. Blood samples were obtained from the tail vein and glycaemia was calculated by a blood glucose test meter (Accu-Chek ® Sensor, Roche, Germany). Body weight was measured using an electronic balance 3 days before wounding and at days 0, 5, 9, 14 and 17 after wounding.
Wound closure was determined by measuring the wound area (px 2 ) on surgery day and on days 4, 7, 11, 14 and 17 after wounding by tracing the wound margin using ImageJ ® software. Wound closure was calculated as a per cent area of the original wound. A wound was considered completely closed when the wound area was equal to zero (Galiano and Michaels 2004) .
Histological analysis
After 7, 11 and 17 days, animals were euthanised by CO 2 inhalation. The wounds were excised in 5 µm thick layers under the fascia, including a 5 mm margin of unwounded skin, bisected and fixed in 10% formalin for 24 hours. The samples were processed by H&E staining for morphological observations (Li, et al. 2008; Ulubayram, et al. 2001 ).
Re-epithelisation grade was measured according to Sinha and Gallagher 2003 established criteria (Sinha and Gallagher 2003) . Results were given in a semiquantitative manner with a score from 0 to 4. 0: re-epithelisation at the edge of the wound, 1: re-epithelisation covering less than half of the wound, 3: re-epithelisation covering more than half of the wound, 3: re-epithelisation covering the entire wound, irregular thickness and 4: re-epithelisation covering the entire wound, normal thickness.
The scale described by Cotran et al. 2000 was used to evaluate resolution phases of inflammatory recovery (Cotran, et al. 2000) . 1: acute inflammation (formation of fibrin clot and pyogenic membrane; migration of leucocytes and polynuclear neutrophils), 2:
predominance of diffuse acute inflammation (predominance of granulation tissue and pyogenic membrane; vascular neogenesis), 3: predominance of chronic inflammation (fibroblast proliferation), 4: resolution and healing (reduction or disappearance of chronic inflammation although occasional round cells may persist).
Statistical analyses
Data are presented as the mean ± standard deviation. Statistical significance was accepted at p < 0.05. Differences in the EE and the release profile before and after gamma sterilization were analyzed by Student's t-test. For multiple group comparisons, one-way ANOVA and post-hoc tests were used. The Bonferroni or Tamhane post-hoc test was applied based on to the result of the Levene test of homogeneity of variances.
All statistical analyses were performed with SPSS 20.0 (SPSS, Inc., Chicago, IL).
Results

Microsphere optimisation
Optimal microencapsulation process was set up by the determination of physicochemical properties of 0.1% rhEGF loaded MS (MS1 to MS4). All MS displayed a similar size and zeta potential ( Figure 1A ). The addition of NaCl to the surfactant solution and the solvent removal phase increased the EE of MS3 up to 67.53 and 4.85 ± 0.17% for MS4, followed by a sustained release phase from day 1 up to 41 days ( Figure 1C ).
Further studies were performed on MS4 formulation based on its higher EE.
3.2. Study of the effect of increasing the rhEGF load and the sterilisation process on
MS properties
Particle size, zeta potential values and MS morphology of 1% rhEGF MS, before and after γ-sterilisation, were similar to the 0.1% loaded formulations (MS4) ( Figure 1A vs. 2A). In addition, ELISA assays demonstrated that the EE was reduced when the rhEGF loading increased (68.82 ± 1.50%) ( Figure 1B vs 2B) . In vitro release profiles show an increment on SAP from 4.85 ± 0.17% for MS4 to 24.55 ± 1.65% for 1% rhEGF MS ( Figure 1C and 2C) . After the γ-sterilisation of the 1% loaded MS, the EE decreased even more (60.01 ± 1.10%) (Figure 2A ), being this difference statistically significant (p<0.05). In accordance with these results, γ-irradiated MS showed a statistically significant decrease in the burst effect (p<0.05), and the differences observed in the release profile were also statistically significant (p<0.05) ( Figure 2C ).
3.3.
In vitro cell culture studies
Bioactivity assay for rhEGF
The effects of microencapsulation and γ-sterilisation on rhEGF bioactivity were quantified in the bioactivity assay. To assess the activity of the growth factor, the ED 50 of rhEGF was quantified. A lower ED 50 value reflects a greater effectiveness of a drug.
The biological activity of rhEGF was not significantly affected by the microencapsulation or sterilisation processes (free rhEGF ED 50 66.95 ± 10.67 pg/ml, rhEGF obtained from PLGA-Alginate MS ED 50 54.89 ± 8.58 pg/ml and rhEGF obtained from PLGA-Alginate MS-γ ED 50 60.77 ± 11.75 pg/ml) (p < 0.05) (Figure 3 ).
In vitro migration assay
Balb/c 3T3 fibroblasts closed the wound from the scratch assay in the presence of 15 ng/ml of rhEGF, faster than the control group (Figure 4) . At 5 h, the extent of wound closure was 40.64 ± 6.57% for free rhEGF, 40.47 ± 7.06% for rhEGF obtained from the release tests (PLGA-Alginate MS) and 7.00 ± 3.00% for the serum-free medium control group. For both treated groups, free rhEGF and rhEGF obtained from the release tests (PLGA-Alginate MS), the differences with the control group reached statistical significance (p<0.05). Complete wound closure of the scratches was achieved in free rhEGF group and rhEGF obtained from the release tests (PLGA-Alginate MS) at 18 h and 24 h, compared to the increased wound area of the serum-free medium control group. rhEGF-treated groups did not change cell morphology. In contrast, in the serumfree medium control group, the elongated and fusiform morphology began to disappear by 5 h. In vitro migration assay shows that cells from the free rhEGF and rhEGF obtained from the release test groups migrated and proliferated, closing the wound completely after 24 h. In the serum-free medium control group, cells did not close the wound thoroughly at 24 h.
In vivo studies
Blood glucose level and body weight
Hyperglycaemia was confirmed 72 hours after streptozocin administration, and the wound induction was performed one week after the STZ treatment. The blood glucose level exceeded 300 mg/dL in all groups during the experiment. Mice showed no adverse reaction to the different treatments through the 17 th day, with no significant differences in body weight in any of the experimental groups.
Wound closure
The skin rapidly contracted to cover the wound. 4 days after wounding, the contraction in the rhEGF MS group was significantly different from the free rhEGF group (25.44 ± 11.15% and 36.43 ± 5.45%, respectively, p<0.01) ( Figure 5A ). Therefore, the rhEGF treated groups (Free rhEGF and rhEGF MS) presented a more reduced wound area (one-way ANOVA, p<0.05) while the control groups were not able to decrease the wound area by the same percentage (14.34 ± 7.82% for the untreated control group, 13.06 ± 8.88% for the vehicle control group and 14.98 ± 6.57% for the empty MS control group). By days 7 and 11 post-wounding, rhEGF MS showed a higher decrease (p<0.05) in the wound area (61.06 ± 8.69% by day 7 and 90.29 ± 3.60% by day 11) in comparison to the free rhEGF group (51.46 ± 10.29% by day 7 and 78.97 ± 4.44% by day 11), which received two additional doses of 75 µg rhEGF per week. Moreover, at days 7 and 11, the wound closure rate was significantly higher in rhEGF MS group in comparison with the other groups. Typical wound images obtained from each treatment group at day 7 are shown in Figure 5C . From 14 days after wounding until the end of the assay, statistically significant differences were no longer detected between any of the studied groups ( Figure 5A ).
Re-epithelisation
At day 7 after wounding, in the rhEGF MS group re-epithelisation starts, partially covering the wound surface (according to Sinha et al. 2003 criteria; 1.13 ± 0.35).
Nevertheless, the other experimental groups showed smaller re-epithelised areas (less than 1.00 in Sinha et al. 2003 criteria) . By day 11, the re-epithelisation was complete but of irregular thickness in the rhEGF MS group (3.25 ± 0.89) while, the untreated control group had an immature complete re-epithelised area (3.88 ± 0.35). However, in the free rhEGF group (2.38 ± 0.93), the vehicle group (2.88 ± 1.46) and the empty MS group (2.75 ± 1.39), the new epithelia did not cover the entire wound surface. 17 days after wounding, all groups showed complete and mature re-epithelised areas with a normal thickness (Figure 6 ).
Inflammation
At day 7, a recovery state between diffuse acute inflammation and predominance of chronic inflammation predominated in the group receiving rhEGF MS, in which fibroblast proliferation prevailed (2.38 ± 0.52) (according to Cotran et al. 2000 criteria) .
In contrast, the other experimental groups did not leave the acute inflammatory state by day 7 (less than 2.00). The differences between rhEGF MS treated group and the other groups reach statistical significance at that point of the study (one-way ANOVA, p<0.05). At day 11 th after wounding, the rhEGF MS and untreated control groups showed complete recovery of the wound (Score 4). Conversely, other experimental groups had not healed completely. By the end of the study, all the groups showed completed resolution of the injury (Figure 7 ).
Discussion
Non-healing chronic diabetic foot ulcers are characterised by an atypical ECM, reepithelisation disturbance and a recurrent inflammatory response. Growth factors, such as rhEGF, are essential for correct dermal and epithelial regeneration. However, it has a short half-life in vivo and requires multiple administrations, restricting its clinical use . To overcome this problem, we propose an alternative protective technique, based on PLGA-Alginate MS for the treatment of chronic wounds, which retains rhEGF biological activity and maintains its sustained release on wound surface.
NaCl. alginate and PLGA, widely used in a broad range of pharmaceutical and biopharmaceutical products (Wenk, et al. 2009 ), were added in order to optimise the MS properties, primarily with the aim of increasing EE. For the optimisation of the MS, the formulations were prepared using 0.1% rhEGF instead of using a model protein, as previously reported in other studies. (Gutierro, et al. 2002) . This delivery system has the advantages of a polymeric therapeutic approach, including biocompatibility, biodegradability and allows a controlled and sustained release of the entrapped drug (Jain 2000; Tessmar and Göpferich 2007) .
The current study found that the addition of NaCl and alginate did not produce significant changes in MS size or zeta potential. Although these results differed from by NaCl, which prevents rhEGF diffusion from the microsphere and becomes MS homogeneous, smooth and regular (Bilati, et al. 2005; Chen, et al. 2004; Perugini, et al. 2001 ). Moreover, the addition of alginate increased EE to 88.11 ± 1.51% due to an increment of the viscosity in the internal aqueous phase (w 1 ) which limits the diffusion of rhEGF from the MS and improves the protein-polymer affinity. These data are in agreement with previous work that showed a significant increase in the SPf66 peptide EE after encapsulation in PLGA-Alginate MS (Mata, et al. 2011 ). The in vitro release studies conducted with MS3 and MS4 showed a similar profile with a sustained rhEGF release for 41 days. Taking into account that the MS properties did not differ between formulations and that the encapsulation efficiency was greater in alginate-containing MS (MS4), the target loading increase to 1%, γ-sterilisation, and further in vitro/in vivo studies were only carried out in the alginate-containing formulation.
The increment in rhEGF target loading, did not affect particle size, zeta potential and particle morphology. However, the EE decreased when the amount of encapsulating rhEGF raised. This finding may be explained by the increased diffusion of rhEGF to the external water phase of the w/o/w emulsion when the loading was increased from 0.1% to 1%. Furthermore, the increase of the amount of rhEGF released in the first 30 minutes (when the surface associated peptide was released) observed in the in vitro release studies of PLGA-Alginate MS and MS4, demonstrate the direct correlation between the increase of rhEGF loading and its distribution on the particle surface. Similar results were also described by Wang et al. 2005 , in which the SAP was improved in the formulation with a higher amount of rhEGF encapsulated (Wang, et al. 2005 ). Regarding to the γ-sterilisation of MS (PLGA-alginate MS-γ), particle size, zeta potential and particle morphology were not affected by the sterilisation process, nevertheless, a statistically significant reduction of EE and a reduced burst effect were detected after γ-sterilisation. These findings are in agreement with Fernández-Carballido et. al 2006, who attributed this decrease to a degradation of the drug during the sterilisation process (Fernández-Carballido, et al. 2006) .
With regard to the in vitro proliferation and bioactivity assays, the results showed that rhEGF maintains its bioactivity after the microencapsulation and γ-sterilisation processes. This view is supported by He et al. 2011 , who demonstrated the stability of recombinant human erythropoietin after its microencapsulation in PLGA MS (He, et al. 2011 ) and Igartua et al. 2008 who demonstrated that SPf66 integrity was maintained after γ-sterilisation (Igartua, et al. 2008 ). In vitro cell migration studies demonstrated that in presence of rhEGF, either free or obtained from release studies of PLGAAlginate MS, the wound area was reduced more and faster than in the control group, illustrating that rhEGF maintains its biological activity when it is incorporated into the MS. In contrast to these results, cells used in control group changed cell morphology, losing their fusiform and elongated form due to the absence of rhEGF in the culture media.
The present study shows that the administration of a single dose of rhEGF MS accelerates the resolution of the inflammatory process and wound closure (in terms of contraction and re-epithelisation) of full-thickness wounds in the streptozocin- As confirmed by the in vivo data, the increased healing effect of rhEGF MS was observed in the first days of the study, at day 4 for the wound closure rate, between 7-11 days for re-epithelisation and at day 7 for inflammatory resolution. These findings confirm the following: (i) microencapsulation into a PLGA-Alginate MS protects the growth factor from the wound environment, making it less vulnerable to protease inactivation and oxidative stress present in the wound area (Chen, et al. 1997; Hardwicke, et al. 2011) . Moreover, it is likely that rhEGF released from EGF MS is still active 11 days after wounding.
(ii) microencapsulation provides sustained release of rhEGF, potentially allowing a reduction in the dosage and number of administrations in rhEGF therapy. A simplified dosage regimen would be a major breakthrough for future clinical application of EGF. Therefore, sustained release could increase rhEGF bioactivity levels in the wound area, thereby inducing REGF phosphorylation, which stimulates fibroblast and keratinocyte proliferation and differentiation. (iii) continuous local administration of free rhEGF does not improve wound healing. Some studies attribute this observation to a maximal activity of rhEGF in the range of ng/ml as opposed to µg/ml (Duncan 2003) .
However, the improved healing effect induced by rhEGF MS loses its statistical significance over time. This could be attributed to the following two reasons: (i) rhEGF accelerates the healing process only at the initial stage of wound repair, indicating that rhEGF may be mostly required just in the early stages of the healing process (Choi, et al. 2008 ). This statement is in agreement with Shirakata et al. 2000 which suggest that rhEGF stimulates proliferation of keratinocytes for only 24 hours after its addition (Shirakata, et al. 2000) .
(ii) streptozocin administration, which ablates pancreatic cells, causes the animal to enter a diabetic state (Takasu, et al. 1991) . This model, although useful, does not accurately reflect the compromised healing process in chronic human wounds. Therefore, diabetes, along with aging or obesity, is only one factor that alters and prolongs the healing process. It has been reported that STZ-treated rats do not necessarily suffer a healing delay as seen in chronic wounds (Davidson 1998; LeGrand 1998; Michaels, et al. 2007 , Ansell, et al. 2012 ). This may explain why the differences between the treated and control groups diminished as the study proceeded.
Conclusions
In this study, to establish an animal model that better fits the human chronic wound healing process. 
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